GQG Partners LLC Increases Holdings in Pfizer Inc. $PFE

GQG Partners LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 36.4% in the 2nd quarter, Holdings Channel reports. The firm owned 131,567 shares of the biopharmaceutical company’s stock after buying an additional 35,075 shares during the quarter. GQG Partners LLC’s holdings in Pfizer were worth $3,168,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its stake in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC lifted its position in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank lifted its position in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 6,415 shares in the last quarter. Sei Investments Co. boosted its holdings in Pfizer by 31.5% in the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after acquiring an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC grew its position in Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after acquiring an additional 31,896 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.4%

Shares of NYSE:PFE opened at $27.97 on Tuesday. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The company has a fifty day simple moving average of $25.34 and a 200 day simple moving average of $26.26. The firm has a market cap of $159.41 billion, a PE ratio of 36.80 and a beta of 0.34. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $28.75.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm’s revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Analyst Ratings Changes

A number of analysts have recently issued reports on PFE shares. Guggenheim dropped their price objective on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Citigroup boosted their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. JPMorgan Chase & Co. lowered their target price on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and an average price target of $28.28.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.